SECUKINUMAB IMPROVES GRAPPA-OMERACT CORE DOMAINS OF PSORIATIC ARTHRITIS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR

Ana-Maria Orbai, M Elaine Husni, Dafna D. Gladman, Ying Ying Leung, Stefan Siebert, William Tillett, Marijn Vis, Olivier Chambenoit, Xiangyi Meng, Philip J. Mease

Research output: Contribution to journalMeeting abstract

Abstract

Background: Secukinumab, a fully human interleukin 17 (IL-17A) monoclonal antibody, has demonstrated efficacy in psoriatic arthritis (PsA) in phase 3 clinical trials.1–4 The PsA core domain set, updated by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and endorsed by Outcome Measures in Rheumatology (OMERACT), aims to improve and standardize the assessment of PsA outcomes.5 Objectives: To report the efficacy of secukinumab vs placebo across individual PsA core domains at week 16 in patients naive to tumor necrosis factor (TNF) inhibitors or who were inadequate responders (TNF-IR), using pooled data from 4 phase 3 FUTURE studies.Methods: Patients with active PsA participated in the phase 3 FUTURE 2, 3, 4, and 5 trials.1–4 Data were pooled for secukinumab 150 mg (load vs. no load), 300 mg, or placebo at the end of the 16-week double-blind period. Efficacy was assessed using multiple clinical and laboratory measures to evaluate the updated GRAPPA-OMERACT PsA core domain set for disease activity, pain, function, and quality of life (Table 1).Results: A total of 2049 patients were included (1436 TNF naive and 613 TNF-IR). Baseline demographics and disease characteristics were broadly similar in all treatment groups. Efficacy results for the core inner circle domains are shown in Table 1.Conclusion: Secukinumab demonstrated efficacy compared with placebo across GRAPPA-OMERACT PsA core domains in the phase 3 clinical trials program, regardless of prior TNF inhibitor use.Reference [1] McInnes IB, et al. Rheumatology. 2017;56:1993-2003; 2. Nash P, et al. Arthritis Res Ther. 2018;20:47; 3. Kivitz A, et al. PANLAR 2018 [abstract 364]; 4. Mease PJ, et al. Ann Rheum Dis. 2018;77:890-897; 5. Orbai AM, et al. Ann Rheum Dis. 2017;76:673-680.Disclosure of Interests: Ana-Maria Orbai Grant/research support from: AbbVie, Celgene, Horizon Pharma, Janssen, Lilly, and Novartis, Consultant for: Lilly, Janssen, Novartis, Pfizer, and UCB, M Elaine Husni Grant/research support from: Janssen, Dafna D Gladman Grant/research support from: AbbVie, Amgen, Celgene, Lilly, Novartis, Pfizer, and UCB, Consultant for: AbbVie, Amgen, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB, Ying Ying Leung Grant/research support from: Abbvie, Novartis, Speakers bureau: Abbvie and Novartis, Speakers bureau: Novartis, Stefan Siebert Grant/research support from: AbbVie, Novartis, Pfizer, Janssen, BMS, Celgene, UCB, and Boehringer Ingelheim, Consultant for: AbbVie, UCB, Pfizer, Janssen, Boehringer Ingelheim, Celgene, and Novartis, Speakers bureau: AbbVie, UCB, Pfizer, Janssen, Boehringer Ingelheim, Celgene, and Novartis, William Tillett Grant/research support from: AbbVie, Celgene, and Lilly, Consultant for: AbbVie, Celgene, Lilly, Novartis, and Pfizer, Speakers bureau: Abbvie, Celgene, Lilly, Janssen, Novartis, UCB, and Pfizer, Marijn Vis Grant/research support from: Novartis, Olivier Chambenoit Shareholder of: Novartis, Employee of: Novartis, Xiangyi Meng Shareholder of: Novartis, Employee of: Novartis, Philip J Mease Grant/research support from: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Consultant for: AbbVie, Amgen, BMS, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Speakers bureau: AbbVie, Amgen, BMS, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer and UCB
Original languageEnglish
Article numberSAT0369
Number of pages2
JournalAnnals of the Rheumatic Diseases
Volume78
Issue numberSuppl 2
DOIs
Publication statusPublished - 27 Jun 2019

Cite this